|
|
|
| The Application of Roxadustat in Patients with Renal Anemia and Its Effects on Inflammatory Mediators and Myocardial Enzymes |
| TIAN Lihui, LIU Fei, GUO Hongping, et al |
| Linfen People's Hospital, Shanxi Linfen 041000, China |
|
|
|
|
Abstract Objective: To investigate the effect of Roxadustat on inflammatory mediators and myocardial enzymes in patients with renal anemia. Methods: According to the principle of random number grouping,90 patients with renal anemia admitted from October 2020 to December 2021 were divided into an observation group and a control group,with 45 patients in each group..The patients in the control group were treated with routine anti anemia therapy,while the patients in the observation group were treated with Roxadustat on the basis of the treatment in the control group,and the therapeutic effects,iron metabolism indicators[serum ferritin (SF),transferrin (TRF),transferrin saturation (TSAT),and ferrimodulin (Hepc)],inflammatory mediators[interleukin-6 (IL-6) and C-reactive protein (CRP)] Myocardial zymogram indicators[phosphocreatine kinase (CK),phosphocreatine kinase isoenzyme (CK-MB),lactate dehydrogenase (LDH)] and adverse reactions were compared. Results: The therapeutic effect,SF,TRF and TSAT levels in the observation group were higher than those in the control group (P<0.05).After treatment,the levels of Hepc,IL-6,CRP,CK,CK-MB and LDH in the observation group were lower than those in the control group (P<0.05).There was no statistical difference between the two groups in the incidence of adverse reactions (P>0.05). Conclusion: Rosalrestat has a good effect on patients with renal anemia.It can effectively improve the level of iron metabolism and inflammatory state,and reduce the indexes of myocardial zymogram,but it has little effect on the occurrence of adverse reactions during treatment.
|
|
|
|
|
|
[1] Yamamoto M,Matsumoto T,Ohmori H,et al.Effect of increased blood flow rate on renal anemia and hepcidin concentration in hemodialysis patients[J].BMC Nephrol,2021,22(1):221-222.
[2] 王佳玉,李建英.慢性肾衰竭微炎症状态与肾性贫血研究近况[J].中国中西医结合肾病杂志,2018,19(11):1029-1031.
[3] 苗畅贤,包品,阎小璐,等.血液透析分别联合血液透析滤过和血液灌流对患者肾性贫血的影响[J].河北医学,2021,27(5):823-826.
[4] 敖利娜,解德琼,唐前容,等.罗沙司他治疗非透析慢性肾脏病患者肾性贫血的疗效观察[J].中华实用诊断与治疗杂志,2021,35(7):732-734.
[5] 康乐,周晶莹,郭夏楠,等.罗沙司他治疗慢性肾脏病5期非透析糖尿病肾脏疾病患者肾性贫血的疗效观察[J].中国实用内科杂志,2022,42(3):238-241.
[6] 孙世仁.铁调素与肾性贫血[J].肾脏病与透析肾移植杂志,2018,27(2):155-156.
[7] 余桂芳,王涛,王少元.罗沙司他治疗肾性贫血的临床疗效及其对炎性因子的影响[J].临床合理用药杂志,2021,14(24):35－37,40:
[8] 李玉,段敬柱.心理应激对冠心病合并2型糖尿病患者PCI术后糖代谢、胰岛素抵抗及炎症介质水平的影响[J].中国健康心理学杂志,2019,27(1):4-6.
[9] 李伟超.应用罗沙司他治疗肾性贫血对患者微炎症因子的影响[J].中国实用医药,2021,16(2):123－125.
[10] 李洁,张新金.促红细胞生成素保护心肌缺血再灌注损伤的研究进展[J].中西医结合心脑血管病杂志,2018,16(22):3277-3279. |
|
|
|
2023, Vol. 29 
